Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers Nicotine to Brain Faster
Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies LXRP completes formation of wholly owned subsidiary, Lexaria Nicotine Corp., to better commercialize opportunities The company is a technology disrupter and has applied for new U.S. patent on its delivery process; it plans to out-license and develop future products Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) patented DehydraTECH™ drug delivery platform has been confirmed in analysis of a second generation lab study on 40 rats…